Demand for cosmetic genitoplasty or vaginoplasty is increasing. Lih Mei Liao, consultant clinical psychologist, and Sarah M Creighton, consultant gynaecologist, argue that surgery carries risks and that alternative solutions to women’s concerns about the appearance of their genitals should be developed.
South Australian research which found a link between cerebral palsy and exposure to herpes viruses has been recognised as among the most significant of the past year by an international panel of neuroscientists.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) has approved the oral contraceptive Lybrel? (90 mcg levonorgestrel/20 mcg ethinyl estradiol) tablets for the prevention of pregnancy in women who elect to use oral contraceptives and who have no known contraindications for this method of contraception.
Very low birth weight infants are significantly more likely to survive when delivered in hospitals with high-level neonatal intensive care units that care for more than 100 such newborns annually than are those delivered in comparable facilities that provide care to fewer than 100 such children every year.
Preterm delivery, and particularly “extreme prematurity” ? defined as less than 32 weeks of gestation ? are major contributors to perinatal sickness and death worldwide.
Low-birth-weight infants are more likely to survive if born in hospitals having high performing Neonatal Intensive Care Units, revealed by researchers in a recent study.
In a pair of studies posted on Biology of Reproduction — Papers in Press, researchers report that results from studies of adolescent female sheep suggest that teenaged girls who become pregnant before reaching full growth may not be able to supply their fetuses with adequate nourishment.
The Food and Drug Administration (FDA) approved Lybrel, the first continuous use drug product for prevention of pregnancy.
A minimally invasive device for treating recurrent stress urinary incontinence in women has been shown to be safe and effective in early clinical trials and is now under review by the US Food and Drug Administration (FDA), says Emory University School of Medicine urologist and trial co-principal investigator Niall Galloway, MD.
Women looking for a simple way to avoid their menstrual period could soon have access the first birth control pill designed to let women suppress monthly menstrual bleeding indefinitely.